Strata Critical Medical (SRTA) Cash & Equivalents (2019 - 2026)

Strata Critical Medical (SRTA) has reported Cash & Equivalents for 8 consecutive years, with $264000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 69.23% year-over-year to $264000.0; the TTM figure through Mar 2026 stood at $264000.0 (down 69.23% YoY), while the FY2025 annual figure was $31.0 million, up 2340.35% from the prior year.
• Cash & Equivalents fell to $264000.0 in Q1 2026 per SRTA's latest filing, from $31.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $186.6 million in Q2 2022 and bottomed at $263000.0 in Q3 2025.
• Historically, Cash & Equivalents has averaged $22.6 million across 5 years, with a median of $2.5 million in 2022.
• On a YoY basis, Cash & Equivalents climbed as much as 2340.35% in 2025 and fell as far as 98.69% in 2025.
• Strata Critical Medical's Cash & Equivalents stood at $3.1 million in 2022, then surged by 803.5% to $27.9 million in 2023, then plunged by 95.45% to $1.3 million in 2024, then surged by 2340.35% to $31.0 million in 2025, then tumbled by 99.15% to $264000.0 in 2026.
• Business Quant data shows SRTA's Cash & Equivalents at $264000.0 in Q1 2026, $31.0 million in Q4 2025, and $263000.0 in Q3 2025.